These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23944848)

  • 1. Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE.
    Ferrín G; Ranchal I; Llamoza C; Rodríguez-Perálvarez ML; Romero-Ruiz A; Aguilar-Melero P; López-Cillero P; Briceño J; Muntané J; Montero-Álvarez JL; De la Mata M
    Liver Int; 2014 Mar; 34(3):438-46. PubMed ID: 23944848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis.
    Ferrín G; Rodríguez-Perálvarez M; Aguilar-Melero P; Ranchal I; Llamoza C; Linares CI; González-Rubio S; Muntané J; Briceño J; López-Cillero P; Montero-Álvarez JL; de la Mata M
    PLoS One; 2015; 10(3):e0118527. PubMed ID: 25789864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients.
    Mustafa MG; Petersen JR; Ju H; Cicalese L; Snyder N; Haidacher SJ; Denner L; Elferink C
    Mol Cell Proteomics; 2013 Dec; 12(12):3640-52. PubMed ID: 24008390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas.
    Long J; Lang ZW; Wang HG; Wang TL; Wang BE; Liu SQ
    Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):296-305. PubMed ID: 20525558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach.
    Lee IN; Chen CH; Sheu JC; Lee HS; Huang GT; Chen DS; Yu CY; Wen CL; Lu FJ; Chow LP
    Proteomics; 2006 May; 6(9):2865-73. PubMed ID: 16586433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma.
    Zekri AR; Bahnassy AA; Alam El-Din HM; Morsy HM; Shaarawy S; Moharram NZ; Daoud SS
    Oncol Rep; 2011 Oct; 26(4):825-31. PubMed ID: 21701780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis.
    Feng JT; Liu YK; Song HY; Dai Z; Qin LX; Almofti MR; Fang CY; Lu HJ; Yang PY; Tang ZY
    Proteomics; 2005 Nov; 5(17):4581-8. PubMed ID: 16240287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
    Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
    J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study.
    Passos-Castilho AM; Lo Turco E; Ferraz ML; Matos C; Silva I; Parise E; Pilau E; Gozzo F; Granato C
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):43-9. PubMed ID: 25822433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of lamin B1 and vimentin as circulating biomarkers for early hepatocellular carcinoma.
    Wong KF; Luk JM
    Methods Mol Biol; 2012; 909():295-310. PubMed ID: 22903723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC.
    Helaly GF; Abou Shamaa LA
    Egypt J Immunol; 2006; 13(1):27-38. PubMed ID: 17974148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system.
    Kanmura S; Uto H; Kusumoto K; Ishida Y; Hasuike S; Nagata K; Hayashi K; Ido A; Stuver SO; Tsubouchi H
    Hepatology; 2007 Apr; 45(4):948-56. PubMed ID: 17393466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases.
    Paradis V; Degos F; Dargère D; Pham N; Belghiti J; Degott C; Janeau JL; Bezeaud A; Delforge D; Cubizolles M; Laurendeau I; Bedossa P
    Hepatology; 2005 Jan; 41(1):40-7. PubMed ID: 15690480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
    Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
    Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating transforming growth factor-β and epidermal growth factor receptor as related to virus infection in liver carcinogenesis.
    Divella R; Daniele A; Gadaleta C; Tufaro A; Venneri MT; Paradiso A; Quaranta M
    Anticancer Res; 2012 Jan; 32(1):141-5. PubMed ID: 22213299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.
    Göbel T; Vorderwülbecke S; Hauck K; Fey H; Häussinger D; Erhardt A
    World J Gastroenterol; 2006 Dec; 12(47):7604-12. PubMed ID: 17171788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity of squamous cell carcinoma antigen (SCCA)-IgM detection in patients with HCV infection and rheumatoid factor seropositivity.
    Biasiolo A; Tono N; Zaninotto M; Merkel C; Fassina G; Plebani M; Gatta A; Pontisso P
    J Med Virol; 2013 Jun; 85(6):1005-8. PubMed ID: 23588726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
    Attallah AM; Shiha GE; Ismail H; Mansy SE; El-Sherbiny R; El-Dosoky I
    Clin Biochem; 2009 Apr; 42(6):455-61. PubMed ID: 19063876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel proteomic biomarker panel for prediction of aggressive metastatic hepatocellular carcinoma relapse in surgically resectable patients.
    Tan GS; Lim KH; Tan HT; Khoo ML; Tan SH; Toh HC; Ching Ming Chung M
    J Proteome Res; 2014 Nov; 13(11):4833-46. PubMed ID: 24946162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy.
    Wu FX; Wang Q; Zhang ZM; Huang S; Yuan WP; Liu JY; Ban KC; Zhao YN
    Cancer Lett; 2009 Jul; 279(2):163-70. PubMed ID: 19268439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.